Bone Density in Breast Cancer: When to Intervene?

This publication has 31 references indexed in Scilit:

• Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
  Journal of Clinical Oncology, 2007
• Teriparatide [Human PTH(1-34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis
  Journal of Bone and Mineral Research, 2006
• Calcium plus Vitamin D Supplementation and the Risk of Fractures
  New England Journal of Medicine, 2006
• Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status
  Journal of Clinical Oncology, 2006
• A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
  New England Journal of Medicine, 2005
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
  The Lancet, 2005
• Adjuvant Docetaxel for Node-Positive Breast Cancer
  New England Journal of Medicine, 2005
• A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
  New England Journal of Medicine, 2004
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
  New England Journal of Medicine, 2002